Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
Launched by ROXANE LABORATORIES · Nov 12, 2009
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
- Exclusion Criteria:
- • Positive test for HIV, Hepatitis B, or Hepatitis C.
- • Treatment with known enzyme altering drugs.
- • History of allergic or adverse response to perindopril or any comparable or similar product.
About Roxane Laboratories
Roxane Laboratories, a subsidiary of Hikma Pharmaceuticals, is a leading provider of generic pharmaceuticals and specialty products in the United States. Committed to enhancing patient access to high-quality medications, Roxane focuses on the development, manufacturing, and commercialization of a diverse range of generic drugs across various therapeutic areas. The company engages in innovative clinical trials to ensure the safety and efficacy of its products, adhering to rigorous regulatory standards. With a strong emphasis on research and development, Roxane Laboratories strives to meet the evolving healthcare needs of patients and healthcare professionals alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials